使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day and thank you for standing by. Welcome to Revolution Medicine's fourth quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
各位好,感謝您撥冗等候。歡迎參加 Revolution Medicines 2025 年第四季財報電話會議。(接線員指示) 請注意,今天的會議將被錄音。
I would now like to hand the conference over to your first speaker today, Ryan Asay, Senior Vice President of Corporate Affairs. Ryan, please go ahead.
現在我想把會議交給今天的第一位講者,企業事務資深副總裁 Ryan Asay。Ryan,請開始。
Ryan Asay - Senior Vice President of Corporate Affairs
Ryan Asay - Senior Vice President of Corporate Affairs
Thank you and welcome everyone to our fourth quarter and full year 2025 earnings call. Joining me on today's call are Dr. Mark Goldsmith, our Chairman and Chief Executive Office; and Jack Anders, our Chief Financial Officer; Dr. Steve Kelsey our President of Research and Development; Dr. Alan Sandler, our Chief Development Officer; Dr. Wei Lin, our Chief Medical Officer; and Anthony Mancini, our Chief Global commercialization Officer, will join us for the Q&A portion of today's call.
謝謝,並歡迎各位參加我們 2025 年第四季及全年財報電話會議。今天與我一同出席的有:我們的董事長兼執行長 Mark Goldsmith 博士;財務長 Jack Anders;研發總裁 Steve Kelsey 博士;開發長 Alan Sandler 博士;醫務長 Wei Lin 博士;以及全球商業化長 Anthony Mancini,他將在今天的問答環節加入我們。
Before we begin, I'd like to remind everyone that certain statements we make during this call will be forward-looking because such statements deal with future events and are subject to many risks and uncertainties. Actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 10-K that is filed with the US Securities and Exchange Commission.
在開始之前,我想提醒各位,我們在本次電話會議中所做的某些陳述可能屬於前瞻性陳述,因為這些陳述涉及未來事件,並受到多項風險與不確定性的影響。實際結果可能與前瞻性陳述中所述內容存在重大差異。如需完整了解這些風險與不確定性,請查閱我們向美國證券交易委員會提交的 Form 10-K 年度報告。
This afternoon we released financial results for the quarter and full year ended December 31, 2025, and recent corporate updates. The press release is available on the investor section of our website at revmed.com.
今天下午,我們已發布截至 2025 年 12 月 31 日止季度及全年財務結果,以及近期公司最新進展。新聞稿可於我們網站 revmed.com 的投資人專區取得。
With that, I'll turn the call over to Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer. Mark?
接下來,我將把電話會議交給 Revolution Medicines 董事長兼執行長 Mark Goldsmith 博士。Mark?
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Thanks, Ryan. Good afternoon and thank you for joining us. We will keep our prepared remarks brief today, highlighting the substantial progress and growing momentum for our pioneering RAS (ON) inhibitor pipeline and outlining several important priorities for the year ahead. Jack Anders will summarize our financial results along with financial guidance for the year ahead.
謝謝,Ryan。各位下午好,感謝加入我們。今天我們的準備發言將保持精簡,重點說明我們在開創性的 RAS(ON)抑制劑產品線所取得的重大進展與日益增強的動能,並概述未來一年幾項重要優先事項。Jack Anders 將總結我們的財務結果,並提供未來一年的財務指引。
At Revolution Medicines, we remain steadfast in our commitment to revolutionizing treatment globally for patients living with RAS addictive cancers through the discovery, development, and delivery of innovative targeted medicines directed against these common mutational drivers of human cancers. As pioneers in the RAS targeting field with a singular focus on RAS-addicted cancers and a great deal of validating data behind us, we are well positioned to continue building on important scientific drug discovery and clinical breakthroughs that have the potential to change standards of care for patients.
在 Revolution Medicines,我們始終堅定致力於透過發現、開發並提供創新標靶藥物,針對這些常見的人類癌症突變驅動因子,從而在全球範圍內革新 RAS 依賴型癌症患者的治療。作為 RAS 標靶領域的先驅,我們專注於 RAS 依賴型癌症,並擁有大量驗證性數據作為後盾;我們具備良好條件,持續在重要的科學藥物發現與臨床突破上再接再厲,這些突破有潛力改變患者的治療標準。
Our efforts throughout 2025 strengthened our leadership position as we advanced our robust pipeline that includes four novel investigational drugs that target the major oncogenic RAS (ON) drivers. Daraxonrasib, our most advanced program, a groundbreaking RAS (ON) multi-selective inhibitor; elironrasib, a differentiated, highly active and well tolerated RAS G12C selective inhibitor; zoldonrasib, an innovative, highly active, and well tolerated RAS G12D selective inhibitor. And our newest clinical compound, RMC-5127, a promising RAS G12V selective inhibitor.
我們在 2025 年的努力鞏固了領導地位,並推進了強健的產品線,其中包括四款針對主要致癌性 RAS(ON)驅動因子的全新研究用藥物。Daraxonrasib,我們最先進的計畫,是一款突破性的 RAS(ON)多選擇性抑制劑;elironrasib,是一款具差異化、活性高且耐受性良好的 RAS G12C 選擇性抑制劑;zoldonrasib,是一款創新、活性高且耐受性良好的 RAS G12D 選擇性抑制劑。以及我們最新的臨床化合物 RMC-5127,一款前景可期的 RAS G12V 選擇性抑制劑。
We have 8 ongoing or planned Phase 3 registrational trials and extensive clinical experience to date, with more than 22,500 patients having received one or more of our RSA inhibitors in the aggregate. This clinical work is built upon the foundation of a strong discovery and preclinical platform that continues pushing the boundaries. Our virtuous cycle of innovation fuels how we discover new ways of targeting RAS through our highly productive tri-complex platform, develop novel investigational drugs through robust and parallel clinical development plans, and systematically expand our commercialization and operational capabilities to deliver potential new therapies to patients globally.
我們目前有 8 項進行中或規劃中的第三期註冊性試驗,並已累積廣泛的臨床經驗;截至目前,累計已有超過 22,500 名患者接受過我們一種或多種 RSA 抑制劑治療。這些臨床工作建立在強大的發現與臨床前平台基礎之上,並持續推進邊界。我們的創新良性循環,驅動我們透過高產出的三元複合體(tri-complex)平台發現新的 RAS 標靶方式,透過強健且並行的臨床開發計畫開發新型研究用藥物,並系統性擴展商業化與營運能力,以向全球患者提供潛在的新療法。
I'll provide an update on our clinical activities in pancreatic cancer, our most advanced clinical program. With more than 90% of pancreatic cancers being RAS-driven, there's a profound need for RAS targeted therapies which we aim to address with multiple registrational trials underway or that we plan to initiate in 2026.
我將就我們在胰臟癌(我們最先進的臨床計畫)方面的臨床活動提供最新進展。由於超過 90% 的胰臟癌由 RAS 驅動,對 RAS 標靶療法存在迫切需求;我們旨在透過多項已在進行或計畫於 2026 年啟動的註冊性試驗來滿足此需求。
Daraxonrasib, our pioneering RAS (ON) multi-selective inhibitor, has shown an unprecedented clinical profile across RAS mutations and lines of therapy, either alone or in combination with standards of care. Our broad conviction around daraxonrasib was further strengthened by the US FDA designation of daraxonrasib as a breakthrough therapy and its award of one of the agency's first commissioners' National Priority vouchers based on its potential to address significant unmet needs in pancreatic cancer.
Daraxonrasib 作為我們開創性的 RAS(ON)多選擇性抑制劑,無論在不同 RAS 突變類型或不同治療線別中,單藥或與標準治療合併使用,均展現前所未見的臨床特徵。我們對 daraxonrasib 的廣泛信心,亦因美國 FDA 將 daraxonrasib 指定為突破性療法而進一步增強;此外,基於其有潛力解決胰臟癌重大未被滿足的需求,daraxonrasib 亦獲頒該機構首批「署長國家優先」憑證之一。
We're currently evaluating daraxonrasib on 3 randomized registrational studies in pancreatic cancer across lines of therapy. RASolute 302, a randomized registrational trial evaluating daraxonrasib monotherapy in second line metastatic disease. As a reminder, RASolute 302 employs a nested trial design. The largest population of patients with tumors carrying a RASG12 mutation in the core in the expanded population that includes patients with tumors carrying other RAS mutations and tumors without a detected RAS mutation.
我們目前正在胰臟癌不同治療線別中,評估 daraxonrasib 的 3 項隨機分派註冊性研究。RASolute 302 是一項隨機分派註冊性試驗,評估 daraxonrasib 單藥用於第二線轉移性疾病。提醒各位,RASolute 302 採用巢狀試驗設計。核心族群中最大的一群患者為腫瘤帶有 RASG12 突變者;擴大族群則包含腫瘤帶有其他 RAS 突變者,以及未檢出 RAS 突變的腫瘤患者。
The trial employs hierarchical testing to maximize the probability of success in the core population and potentially enable a broad label not requiring biomarker testing. With global enrollment now complete, we expect a readout to occur in the first half of 2026.
該試驗採用階層式檢定,以最大化核心族群的成功機率,並可能促成不需生物標記檢測的廣泛適應症標示。目前全球收案已完成,我們預期將於 2026 年上半年讀出結果。
In earlier lines of therapy, two randomized registrational studies were recently initiated. RASolute 303 is evaluating both daraxonrasib monotherapy and daraxonrasib in combination with chemotherapy and first-line metastatic disease. Evaluating both monotherapy and combination approaches may enable treatment optionality for physicians and patients.
在較早期的治療線別方面,近期已啟動兩項隨機分派註冊性研究。RASolute 303 正在評估 daraxonrasib 單藥,以及 daraxonrasib 與化療合併用於第一線轉移性疾病。同時評估單藥與合併治療策略,可能為醫師與患者提供治療選擇彈性。
RASolute 304 is evaluating daraxonrasib monotherapy in the adjuvant setting in patients with resectable disease after receiving conventional surgery and perioperative chemotherapy. The data we've collected to date support our strong conviction that these studies have the potential to establish new global standards of care across lines of treatment for patients living with pancreatic cancer.
RASolute 304 正在評估 daraxonrasib 單藥用於輔助治療情境,對象為可切除疾病患者,在接受傳統手術與圍手術期化療後使用。我們迄今收集的數據支持我們的高度信心:這些研究有潛力在不同治療線別中,為胰臟癌患者建立新的全球治療標準。
Zoldonrasib, our covalent G12D selective inhibitor, is another first of its kind compound that has shown a highly differentiated safety and tolerability profile. We recently disclosed encouraging initial data from patients with metastatic pancreatic cancer receiving first line treatment with the combination of zoldonrasib and FOLFIRINOX.
Zoldonrasib,我們的共價結合型 G12D 選擇性抑制劑,是另一款同類首創的化合物,並展現高度差異化的安全性與耐受性特徵。我們近期揭露了令人鼓舞的初步數據,來自接受 zoldonrasib 與 FOLFIRINOX 合併作為第一線治療的轉移性胰臟癌患者。
The initial safety and tolerability profile for the combination of both treatments was largely consistent with the well-known profile of modified FOLFIRINOX alone, and a high zoldonrasib dose intensity was maintained. As of the date cutoff date, 63% of patients achieved a partial response, either confirmed or pending confirmation. The disease control rate was 95%, and the vast majority of patients remained on treatment.
兩種治療合併的初步安全性與耐受性特徵,大致與單用改良版 FOLFIRINOX 的既知特徵一致,且維持了較高的 zoldonrasib 劑量強度。截至資料截止日,63% 的患者達到部分緩解,包含已確認或待確認者。疾病控制率為 95%,且絕大多數患者仍持續接受治療。
With these data reinforcing confidence in this compelling G12D selective inhibitor, we plan to advance two first line registrational combination studies this year. Today, we're pleased to announce that RASolute 305 has been initiated. RASolute 305 is a randomized double-blind placebo controlled trial that is evaluating zoldonrasib in combination with investigators' choice of either gemcitabine, nab-paclitaxel, or modified FOLFIRINOX chemotherapy compared to investigators' choice of chemotherapy with placebo.
在這些數據進一步強化我們對此具吸引力的 G12D 選擇性抑制劑之信心下,我們計畫於今年推進兩項第一線註冊性合併研究。今天,我們很高興宣布 RASolute 305 已啟動。RASolute 305 是一項隨機分派、雙盲、安慰劑對照試驗,評估 zoldonrasib 與研究者選擇之化療(吉西他濱、nab-紫杉醇,或改良版 FOLFIRINOX)合併使用,並與研究者選擇之化療合併安慰劑進行比較。
RASolute 309 will evaluate the RAS (ON) inhibitor doublet combination of zoldonrasib plus daraxonrasib and we plan to initiate this trial in the second half of 2026. We plan to share clinical data from the initial trial of the zoldonrasib plus gemcitabine, nab-paclitaxel combination and the zoldonrasib plus daraxonrasib RAS (ON) inhibitor doublet combination in PDAC at one or more medical meetings this year.
RASolute 309 將評估 RAS(ON)抑制劑雙聯組合 zoldonrasib 加 daraxonrasib,我們計劃於 2026 年下半年啟動此試驗。我們計劃於今年在一個或多個醫學會議上分享 PDAC 中 zoldonrasib 加吉西他濱(gemcitabine)、白蛋白結合型紫杉醇(nab-paclitaxel)組合,以及 zoldonrasib 加 daraxonrasib 的 RAS(ON)抑制劑雙聯組合之初始試驗臨床數據。
A second area of focus in which we've shown continued clinical advancement is non-small cell lung cancer. With approximately 30% of non-small cell lung cancers harboring a RAS mutations, including 18% with non-G12C mutations, this tumor type remains a key priority. To date we've shown encouraging initial safety tolerability and anti-tumor activity in patients with RAS mutant lung cancers across our three lead compounds that supports their potential to establish new standards of care, and we are building a set of registrational trials accordingly.
我們持續展現臨床進展的第二個重點領域是非小細胞肺癌。約有 30% 的非小細胞肺癌帶有 RAS 突變,其中包括 18% 為非 G12C 突變,使得此腫瘤類型仍是關鍵優先事項。迄今為止,我們在三項主要候選化合物中,於 RAS 突變肺癌患者身上展現令人鼓舞的初步安全性、耐受性與抗腫瘤活性,支持其建立新照護標準的潛力,我們也據此規劃並推進一系列註冊性試驗。
RASolve 301, our global randomized trial evaluating daraxonrasib monotherapy in previously treated patients, continues enrolling patients across sites both in the US and globally. We anticipate substantially completing enrollment this year. We also expect to disclose our plans for advancing daraxonrasib combination therapy and first line non-small cell lung cancer this year.
RASolve 301 是我們的全球隨機試驗,用於評估 daraxonrasib 單藥治療於既往接受治療患者中的療效,目前持續在美國及全球各地試驗中心招募受試者。我們預期今年將大致完成招募。我們也預計今年將揭露推進 daraxonrasib 聯合治療以及一線非小細胞肺癌的相關計畫。
With zoldonrasib and elironrasib, we've reported highly encouraging safety tolerability and anti-tumor activity data from previously treated patients with lung tumors harboring RAS G12D or G12C mutations respectively. The zoldonrasib monotherapy expansion cohort is fully enrolled, and earlier this year, zoldonrasib was awarded breakthrough therapy designation, making it our third RAS (ON) inhibitor to have received this distinction.
針對 zoldonrasib 與 elironrasib,我們已分別在帶有 RAS G12D 或 G12C 突變的肺部腫瘤既往治療患者中,報告了高度令人鼓舞的安全性、耐受性與抗腫瘤活性數據。zoldonrasib 單藥擴增隊列已完成招募,且在今年稍早,zoldonrasib 獲授予突破性療法認定,使其成為我們第三個獲得此項殊榮的 RAS(ON)抑制劑。
Building on these milestones, we are preparing to initiate RASolve 308, a first randomized registrational trial of zoldonrasib in combination with standard-of-care as a first line treatment for patients with metastatic RAS G12D, non-small cell lung cancer. For elironrasib, we continue to evaluate this compelling G12C selective inhibitor that has demonstrated a differentiated clinical profile in both G12C inhibitor naive and G12C inhibitor experienced lung cancer patients.
在這些里程碑的基礎上,我們正準備啟動 RASolve 308,這將是首個針對轉移性 RAS G12D 非小細胞肺癌患者、以一線治療為目的,評估 zoldonrasib 與標準治療(standard-of-care)聯用的隨機註冊性試驗。至於 elironrasib,我們持續評估這項具吸引力的 G12C 選擇性抑制劑;其在 G12C 抑制劑未治療(naive)與曾接受 G12C 抑制劑治療(experienced)的肺癌患者中,皆展現出差異化的臨床特徵。
We've reported encouraging results with monotherapy or in combinations with either pembrolizumab or as part of a RAS (ON) inhibitor doublet with daraxonrasib, and as we consider multiple approaches, we plan to share an update on a registrational strategy for elironrasib this year.
我們已報告其單藥治療或與 pembrolizumab 聯用,或作為與 daraxonrasib 組成的 RAS(ON)抑制劑雙聯方案之令人鼓舞結果;在我們評估多種策略之際,計劃於今年分享 elironrasib 的註冊性策略更新。
The third area of focus, colorectal cancer, remains of high interest and engagement for the company. Approximately 50% of the patients with colorectal cancer harbor a RAS mutation. Given the genetically complex and heterogeneous nature of the disease, combinatorial approaches are key to maximizing clinical impact. We have a range of studies underway including evaluating RAS (ON) inhibitor doublets and evaluating RAS (ON) inhibitors with current standards of care and with other novel approaches. We plan to provide visibility into combination data in colorectal cancer this year as we work toward prioritizing registrational opportunities.
第三個重點領域為大腸直腸癌,仍是公司高度關注並積極投入的方向。約有 50% 的大腸直腸癌患者帶有 RAS 突變。鑑於該疾病在基因層面複雜且具異質性,組合式治療策略是最大化臨床影響的關鍵。我們已啟動多項研究,包括評估 RAS(ON)抑制劑雙聯方案,以及評估 RAS(ON)抑制劑與現行標準治療及其他新穎策略的聯用。我們計劃於今年提供大腸直腸癌的組合數據能見度,同時推進並優先排序註冊性機會。
Our development efforts include several clinical collaborations studying our RAS (ON) inhibitors with new targeted therapies in clinical development. Our collaboration with Tango Therapeutics is studying our RAS (ON) inhibitors in combination with vopimetostat, Tango's MTA cooperative PRMT5 inhibitor in patients with tumors carrying both a RAS mutation and MTAP deletion.
我們的開發工作亦包含多項臨床合作,研究將我們的 RAS(ON)抑制劑與臨床開發中的新型標靶療法聯用。我們與 Tango Therapeutics 的合作,正在研究將我們的 RAS(ON)抑制劑與 vopimetostat(Tango 的 MTA 協同 PRMT5 抑制劑)聯用,用於腫瘤同時具有 RAS 突變與 MTAP 缺失的患者。
We also recently entered into a clinical collaboration with Bristol-Myers Squibb to evaluate daraxonrasib in combination with navlimetostat, its MTA cooperative PRMT5 inhibitor, in patients with pancreatic cancer whose tumors carry both a RAS mutation and MTAP deletion. This collaboration extends our commitment to evaluating novel targeted agents such as PRMT5 inhibitors that may be appropriate to combine with RAS (ON) inhibitors in some settings.
我們近期也與百時美施貴寶(Bristol-Myers Squibb)達成臨床合作,評估 daraxonrasib 與 navlimetostat(其 MTA 協同 PRMT5 抑制劑)聯用,用於腫瘤同時具有 RAS 突變與 MTAP 缺失的胰臟癌患者。此合作延伸了我們對評估新型標靶藥物(如 PRMT5 抑制劑)的承諾;在某些情境下,這些藥物可能適合與 RAS(ON)抑制劑聯用。
Our ongoing collaboration with Summit Therapeutics is evaluating our RAS (ON) inhibitor with Summit's PD1 VEGF bi-specific antibody ivonescimab across multiple solid tumor settings. The first patient in this trial was recently dosed. We recently brought our fourth RAS (ON) inhibitor, the RAS (ON) G12V selective inhibitor RMC-5127 into the clinic and announced that the first patient had been dosed in the first in human trial. We expect to identify a recommended monotherapy Phase 2 dose for this compound in the second half of 2026.
我們與 Summit Therapeutics 的持續合作,正在多種實體腫瘤情境中評估我們的 RAS(ON)抑制劑與 Summit 的 PD1/VEGF 雙特異性抗體 ivonescimab 的聯用。該試驗近期已完成首位患者給藥。我們近期也將第四個 RAS(ON)抑制劑——RAS(ON)G12V 選擇性抑制劑 RMC-5127——推進至臨床,並宣布首個人體(first-in-human)試驗已完成首位患者給藥。我們預期於 2026 年下半年為該化合物確定建議的單藥第二期(Phase 2)劑量。
As leaders in developing treatment strategies for patients with RAS-addictive cancers, we recognize the importance of continuing to invest in new approaches that advance the science and have the potential to further transform treatment paradigms. Our discovery team continues pioneering novel new approaches, including an innovative new class of RAS (ON) inhibitors from our laboratory designed to overcome RAS-driven drug resistance and thereby extend the clinical benefit of RAS (ON) inhibitors.
作為為 RAS 依賴型(RAS-addictive)癌症患者開發治療策略的領導者,我們深知持續投資於推進科學、並有潛力進一步改變治療典範的新方法之重要性。我們的探索研究團隊持續開創新穎方法,包括由我們實驗室設計的一種創新新類別 RAS(ON)抑制劑,旨在克服 RAS 驅動的藥物抗性,從而延長 RAS(ON)抑制劑的臨床效益。
As we disclosed in January, in preclinical pancreatic cancer and non-small cell lung cancer models that had developed resistance to daraxonrasib, treatment with a representative compound from this new class, RMO55 drove deep and durable regressions. This year, we plan to share more information about this new class of compounds at a scientific meeting and later in the year to begin clinical development of the first compound from this class as our fifth investigational clinical stage RAS (ON) inhibitor.
如我們在一月所揭露,在已對 daraxonrasib 產生抗性的臨床前胰臟癌與非小細胞肺癌模型中,使用此新類別的代表性化合物 RMO55 治療,可帶來深度且持久的腫瘤退縮。今年我們計劃在科學會議上分享更多關於此新類別化合物的資訊,並於今年稍晚啟動該類別首個化合物的臨床開發,使其成為我們第五個處於臨床階段的研究性 RAS(ON)抑制劑。
As late stage programs, notably daraxonrasib, advance toward possible commercialization, we are committed to building a world-class end-to-end global oncology enterprise to deliver compelling targeted therapies to patients with RAS-addicted cancers. We have established a strong operational foundation to move with speed and agility to ensure a successful first commercial launch initially focused in the US market.
隨著後期計畫(尤其是 daraxonrasib)朝向潛在商業化推進,我們致力於打造世界級、端到端的全球腫瘤事業體,以向 RAS 依賴型癌症患者提供具吸引力的標靶療法。我們已建立堅實的營運基礎,以快速且靈活地推進,確保首次商業上市成功,並將初期重點聚焦於美國市場。
To that end, we have made key strategic hires to form a strong leadership team of professionals who have established track records and launched some of the most impactful oncology products in recent years. In addition to recently onboarding regional field sales leadership to support the US launch, recruitment for our first field sales team is now underway.
為此,我們已進行關鍵策略性招募,組建一支強大的領導團隊;其成員具備經驗證的實績,並在近年成功推出多項最具影響力的腫瘤產品。除近期已到任的區域外勤銷售領導以支援美國上市外,我們首支外勤銷售團隊的招募目前也已展開。
I'd now like to turn the call over to Jack Anders, our CFO, to summarize our fourth quarter financial results and forward-looking guidance. Jack?
接下來我想把電話會議交給我們的財務長 Jack Anders,請他總結我們第四季的財務結果以及前瞻性指引。Jack?
Jack Anders - Chief Financial Officer
Jack Anders - Chief Financial Officer
Thank you, Mark. We ended the fourth quarter of 2025 with $2.03 billion in cash and investments. In 2025 we entered into our innovative and flexible strategic partnership with Royalty Pharma, which provided us access to up to $2 billion in committed capital under the terms of the agreement. We received the first royalty monetization tranche of $250 million in June 2025. And there remains an additional $1.75 billion in future committed capital under this arrangement.
謝謝你,Mark。截至 2025 年第四季末,我們的現金及投資為 20.3 億美元。2025 年,我們與 Royalty Pharma 建立了創新且具彈性的策略合作夥伴關係,依協議條款使我們可取得最高達 20 億美元的承諾資金。我們於 2025 年 6 月收到首筆權利金變現(royalty monetization)分期款 2.5 億美元。在此安排下,未來仍有額外 17.5 億美元的承諾資金可供取得。
Turning to expenses, R&D expenses for the fourth quarter of 2025 for $294.9 million compared to $188.1 million for the fourth quarter of 2024. The increase in R&D expenses was primarily due to increases in clinical trial and manufacturing expenses related to our multiple ongoing clinical development programs and an increase in personnel related expenses and stock-based compensation expense associated with additional headcount.
談到費用,2025 年第四季研發(R&D)費用為 2.949 億美元,相較於 2024 年第四季的 1.881 億美元。研發費用增加主要是由於與我們多項正在進行的臨床開發計畫相關的臨床試驗與製造費用增加,以及因新增人力而帶動的人員相關費用與以股份為基礎之薪酬費用增加。
G&A expenses for the fourth quarter of 2025 were $66.7 million compared to $28.2 million for the fourth quarter of 2024. Increase in G&A expenses was primarily due to increases in commercial preparation activities and personnel related expenses and stock-based compensation expense associated with additional headcount.
2025 年第四季一般及行政(G&A)費用為 6,670 萬美元,相較於 2024 年第四季的 2,820 萬美元。G&A 費用增加主要是由於商業化準備活動增加,以及因新增人力而帶動的人員相關費用與以股份為基礎之薪酬費用增加。
Net loss for the fourth quarter of 2025 was $364.9 million compared to $194.6 million for the fourth quarter of 2024. The increase in net loss was primarily due to higher operating expenses as described earlier. Net loss for the fourth quarter of 2025 also included specific non-cash charges of $33.7 million in stock-based compensation expense, $12.6 million in non-cash warrant expense related to a mark-to-market change in the fair value of warrants we inherited as part of our EQRx acquisition. And $11.9 million in non-cash interest expense related to the accounting treatment for our Royalty Pharma arrangement. Full year 2025 financial results are available in our corresponding press release and also included in our Form 10-K that was filed with the SEC this afternoon.
2025 年第四季淨損為 3.649 億美元,相較於 2024 年第四季的 1.946 億美元。淨損增加主要是由於如前所述營運費用較高。2025 年第四季淨損亦包含特定非現金費用:以股份為基礎之薪酬費用 3,370 萬美元、與我們在收購 EQRx 時承接之認股權證公允價值按市價重估變動相關的非現金認股權證費用 1,260 萬美元。以及與我們 Royalty Pharma 安排之會計處理相關的非現金利息費用 1,190 萬美元。2025 全年財務結果已於相應新聞稿中提供,並亦包含於我們今日下午向 SEC 提交的 Form 10-K 中。
Turning to financial guidance, we would like to note that we are switching the forward-looking financial guidance we provide from GAAP net loss to GAAP operating expenses for fiscal year 2026. Switch to GAAP operating expenses is intended to provide expectations on our anticipated level of spend for 2026 in a more straightforward and easier to follow manner. As GAAP net loss includes certain non-cash items within non-operating income and expense, such as the change in fair value of the warrant liability and non-cash interest expense associated with our Royalty Pharma arrangement.
談到財務指引,我們想指出,我們將把 2026 會計年度所提供的前瞻性財務指引,從 GAAP 淨損改為 GAAP 營運費用。改採 GAAP 營運費用旨在以更直接且更易於理解的方式,提供我們對 2026 年預期支出水準的展望。因為 GAAP 淨損包含某些非現金項目於營業外收入與費用之中,例如認股權證負債公允價值變動,以及與我們 Royalty Pharma 安排相關的非現金利息費用。
With that said, we expect full year 2026 GAAP operating expenses to be between $1.6 billion and $1.7 billion. Which includes estimated non-cash stock-based compensation expense of between $180 million and $200 million. The increase in expected GAAP operating expenses for 2026 is a result of the progression and expansion of our clinical development programs, in particular, the multiple ongoing and planned registrational studies we have outlined as priorities.
在此基礎上,我們預期 2026 全年 GAAP 營運費用將介於 16 億至 17 億美元之間。其中包含估計的非現金以股份為基礎之薪酬費用約 1.8 億至 2.0 億美元。2026 年預期 GAAP 營運費用增加,係由於我們臨床開發計畫的推進與擴展,特別是我們已列為優先事項的多項正在進行及規劃中的註冊性研究。
We also expect higher expenses in 2026 as a result of increased commercial preparation activities as we continue to build and expand our organizational capabilities in preparation for becoming a global commercial stage company.
我們亦預期 2026 年費用將因商業化準備活動增加而上升,因為我們持續建立並擴充組織能力,以為成為全球商業化階段公司做準備。
That concludes the financial portion. I will now turn the call back over to Mark.
以上為財務部分。我現在把電話交回給 Mark。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Thank you, Jack. 2025 was a pivotal year for RevMed, and 2026 is poised to be one of substantial impact as we seek to create the industry leading global targeted medicines franchise for patients with RAS-addictive cancers. We believe that each asset in our pipeline has the potential to transform the treatment landscape for these difficult to treat cancers.
謝謝你,Jack。2025 年對 RevMed 而言是關鍵的一年,而 2026 年有望帶來重大影響;我們致力於為 RAS 依賴型癌症患者打造業界領先的全球標靶藥物產品組合。我們相信,我們研發管線中的每一項資產都有潛力改變這些難以治療癌症的治療格局。
With key milestones across our clinical programs, advancing new programs to the clinic, continued investment in innovation, and preparing for our first commercial launch, we are well set up for the future, building on our foundational achievements to date. Of course, none of the work we do would be possible without the partnership and ongoing support of healthcare providers, patients and caregivers and investors, and the remarkable dedication and efforts of RevMed employees.
隨著我們臨床計畫的關鍵里程碑、推進新計畫進入臨床、持續投資創新,以及為我們首次商業化上市做準備,我們已為未來奠定良好基礎,並在迄今的基礎性成果上持續前進。當然,若沒有醫療照護提供者、患者與照護者以及投資人的合作與持續支持,以及 RevMed 員工卓越的投入與努力,我們所做的一切都不可能實現。
With that, I'll turn the call over to the operator for the Q&A portion of today's call. Q&A
接下來,我把電話交給接線員,進入今天電話會議的問答環節。問答
Operator
Operator
(Operator Instructions)
(接線員指示)
Jonathan Chang, Leerink Partners.
Jonathan Chang,Leerink Partners。
Albert Agustinus, Ph.D. - Analyst
Albert Agustinus, Ph.D. - Analyst
Hi, this is Albert Agustinus on for Jonathan Chang. Thanks for taking our question. I was just wondering, could you please share your thoughts or clarifying your plans to advance the director as a combination in first-line non-small cell lung cancer this year? Are you still guiding towards the initiation of a registrational trial for, in this setting? Thank you.
您好,我是代 Jonathan Chang 提問的 Albert Agustinus。感謝讓我們提問。我想請教,您能否分享一下您對於今年推進該藥物作為第一線非小細胞肺癌聯合療法的想法,或釐清相關計畫?您是否仍指引在此適應症啟動一項註冊性試驗?謝謝。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Thanks, Albert, for your question. So I think you're asking about our plans for daraxonrasib in first-line lung cancer. We still have high commitment to continue developing daraxonrasib in lung cancer and particularly in first line. Maybe, Dr. Kelsey could comment on higher resolution answer to that.
謝謝你,Albert,謝謝你的問題。我想你是在問我們對 daraxonrasib 用於第一線肺癌的計畫。我們仍高度承諾持續在肺癌領域開發 daraxonrasib,特別是在第一線。也許 Kelsey 醫師可以就此提供更具體的回覆。
Steve Kelsey - President - Research and Development
Steve Kelsey - President - Research and Development
The reality is that there are a number of options available to us. We continue to both dose optimize daraxonrasib in combination with the -- combination of partners that you might expect us to use for that indication and also do efficacy testing to get the requisite proof concept required to invest in a large space through trials, so as soon as we have that information and a plan to go with it, we'll be able to share it with you. And I think we've committed to providing more information that during the course of this week.
實際情況是,我們有多種可行選項。我們持續在 daraxonrasib 的聯合療法上同時進行劑量最佳化——與你可能預期我們會用於該適應症的合作藥物組合——並且也進行療效測試,以取得投入大型適應症試驗所需的概念驗證(proof of concept)。因此,一旦我們掌握相關資訊並形成可執行的計畫,我們就能與各位分享。而且我想我們也已承諾會在本週期間提供更多資訊。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
And if I could just add, I think the other element to this, of course, is that we just started patient dosing patients with ivonescimab in combination with the RAS (ON) inhibitors that obviously has fairly act on how we think about lung --
另外如果我可以補充,當然還有另一個因素是,我們剛開始讓患者接受 ivonescimab 與 RAS (ON) 抑制劑的聯合用藥,這顯然會相當影響我們對肺癌的思考--
Albert Agustinus, Ph.D. - Analyst
Albert Agustinus, Ph.D. - Analyst
Understood. Thank you.
了解。謝謝。
Operator
Operator
Brian Cheng, JPMorgan.
Brian Cheng,JPMorgan。
Brian Cheng - Analyst
Brian Cheng - Analyst
Hey, guys. Thanks for taking our questions this afternoon. As we get closer to the top-line for the second-line PDAC trial, what is your latest thought on the efficacy measure that we could get at the time of the top-line? And I'm just curious if you can provide a bit more color on the rates of events, towards this upcoming top-line. Thank you.
各位好。感謝今天下午回答我們的問題。隨著我們更接近二線 PDAC 試驗的主要(top-line)結果,您目前對於在公布 top-line 時點可能取得的療效衡量指標有何最新看法?另外也想請您就這次即將公布的 top-line 結果之前的事件發生率(event rates)提供更多說明。謝謝。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Hi, Brian, thanks for your questions. Of course we've entered the period in which we indicated we'd be providing a disclosure, so I don't think we'll be able to give you higher resolution today, that doesn't seem like the right time to do that. It is an OS event driven readout. And the study's powered for OS, but it's of course also power overpowered than for PFS, so we'll have an interim read on that information. I don't think we'll be able to provide any expectations other than that we are directly comparing the standard of care, and that will be the set of benchmarks that will be used in our analysis.
嗨,Brian,謝謝你的問題。我們當然已進入先前所指稱將進行揭露的期間,因此我想今天我們無法提供更高解析度的資訊,現在似乎不是合適的時點。這是一項以 OS 事件驅動的讀出。該研究以 OS 作為主要終點並據此設計檢定力(powered),但當然對 PFS 也具備(甚至更高的)檢定力,因此我們也會有一個期中(interim)讀出可供參考。除了我們是直接與標準治療(standard of care)進行比較之外,我想我們無法提供任何其他預期;而這也將是我們分析所採用的基準。
Brian Cheng - Analyst
Brian Cheng - Analyst
Got it. Thank you.
了解。謝謝。
Operator
Operator
Michael Schmidt, Guggenheim.
Michael Schmidt,Guggenheim。
Michael Schmidt - Analyst
Michael Schmidt - Analyst
Hey, good afternoon. Thanks for taking my questions and congrats on all the progress. Mark, I had one on your ongoing and planned studies in first-line pancreatic cancer. So obviously, there's a lot of excitement among physicians and patients in the pancreatic cancer community around daraxonrasib.
嗨,下午好。感謝回答我的問題,也恭喜各位取得所有進展。Mark,我有一個問題是關於你們在第一線胰臟癌正在進行及規劃中的研究。很明顯地,胰臟癌社群的醫師與患者對 daraxonrasib 都非常期待。
We've heard from docs more recently that if approved, they think that over 90% of their second line patients could go on daraxonrasib within months of approval. And so when you think about that, to what degree do you think daraxonrasib is used in your first line studies post-progression in the control arm could potentially impact our outcomes in RASolute 303 and 305 and how important is it to demonstrate OS in these studies in the first place? Thank you.
我們最近從醫師那邊聽到,如果獲批,他們認為在獲批後的幾個月內,超過 90% 的二線患者都可能會使用 daraxonrasib。因此,當你這樣思考時,你認為在你們的一線研究中,對照組在疾病進展後使用 daraxonrasib 的程度,可能會在多大程度上影響我們在 RASolute 303 與 305 的結果?以及在一開始就於這些研究中證明 OS(總生存期)有多重要?謝謝。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Okay, thanks, Michael, I think I understand the question. To what extent does the availability of an approved daraxonrasib with a second line label potentially provide a complication with some form of crossover for patients from the chemo arm in the second line study, in the 302 study.
好的,謝謝你,Michael,我想我理解這個問題。已獲核准且帶有二線適應症標籤的 daraxonrasib 的可及性,在 302 這項二線研究中,是否可能因某種形式的交叉用藥(crossover)而使化療組患者轉用,從而帶來複雜性?
There is some potential risk for that. Of course, the label would not necessarily indicate ability to cross over unless somebody was declared that they were now formally a second line patient. We wouldn't be able to speak to what somebody might do off label, but there is some risk associated with that. We have the ability to address that, both through timing. We were moving forward with that first line trial and it will be some period of time before the FDA would review and potentially approve the product.
確實存在一些潛在風險。當然,除非有人被宣告其已正式成為二線患者,否則標籤本身未必會指示可以交叉用藥。我們無法評論有人可能會如何進行適應症外用藥(off label),但確實有一些相關風險。我們有能力處理這個問題,包含透過時程安排。我們正在推進那項一線試驗,而在 FDA 審查並可能核准該產品之前,還會有一段時間。
So I think during that period we can probably establish some significant momentum and buffer against that concern. And the other contribution to solving that is geography. And we do expect that outside the United States, patients will enroll in the trial and contribute significantly. And in those settings, it's not likely that the product would be approved yet during the early course of the study.
所以我認為在那段期間,我們大概可以建立相當的動能,並形成緩衝,以降低這項疑慮。另外一個有助於解決此問題的因素是地理分布。我們確實預期美國以外的患者會納入試驗並做出重要貢獻。而在那些地區,在研究早期階段該產品不太可能就已獲批。
Michael Schmidt - Analyst
Michael Schmidt - Analyst
Makes sense. Thank you.
了解。謝謝。
Operator
Operator
Charles Zu, LifeSci Capital.
Charles Zu,LifeSci Capital。
Charles Zhu - Equity Analyst
Charles Zhu - Equity Analyst
Hey, good afternoon, everyone. Congrats on all the progress, and thanks for taking the questions. I have a couple regarding some of your ongoing partnered collaborations. First, can you talk about your decision to also combine your pipeline assets with Bristol's PRMT5 inhibitor and how this kind of fits in context with your ongoing collaboration with Tango?
嗨,各位下午好。恭喜你們取得所有進展,也謝謝你們回答問題。我有幾個問題,關於你們正在進行的一些合作夥伴協作。首先,你們能談談為何決定也將你們的管線資產與百時美施貴寶(Bristol)的 PRMT5 抑制劑做聯合?以及這在你們與 Tango 的既有合作脈絡中是如何契合的?
And second, your collaboration with ivonescimab, at what point might you make go/no-go to decisions on later-stage clinical development with your pipeline assets? And how do you weigh not only the emerging combination data that you're generating, but also the broader landscape among the various HARMONY trials shaping out? Thank you.
第二,你們與 ivonescimab 的合作方面,你們會在什麼時間點對於是否推進到後期臨床開發(go/no-go)做出決策?你們如何權衡不僅是你們正在產生的新興聯合用藥數據,也包括各項 HARMONY 試驗逐步成形所反映的更廣泛競爭格局?謝謝。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Thanks, Charles. I appreciate those questions, really two different topics. One is PRMT5 inhibitors and why is this -- or support assessment of RAS(ON) inhibitors in combination with more than one PRMT5 inhibitor. To some extent, we had already established that precedence because we have an ongoing collaboration with both Amgen and Tango.
謝謝你,Charles。我很感謝這些問題,確實是兩個不同主題。第一個是 PRMT5 抑制劑:為什麼要——或說為什麼要支持評估 RAS(ON) 抑制劑與不只一種 PRMT5 抑制劑的聯合。某種程度上,我們其實已經建立了這樣的先例,因為我們與 Amgen 以及 Tango 都有正在進行的合作。
And the PRMT5 inhibitors appear to be emerging as a potentially important new target class of therapies for patients with MTAP gene deletion. So it makes sense for us to make that -- to make our compounds which are differentiated and compelling and make them available to others who have PRMT5 inhibitors.
而 PRMT5 抑制劑似乎正逐漸成為一個可能很重要的新型治療標的類別,適用於具有 MTAP 基因缺失的患者。因此,對我們而言,讓我們具差異化且具吸引力的化合物可供其他擁有 PRMT5 抑制劑的夥伴使用,是合理的。
This isn't really a signal or a vote on our part about any particular inhibitor. It doesn't speak at all to the work that's ongoing with Tango or Amgen. It's rather more of an inclusive approach and to allow our compounds to be considered in other context as well.
這並不真正代表我們對任何特定抑制劑的訊號或投票。這也完全不影響我們與 Tango 或 Amgen 正在進行的工作。更像是一種更具包容性的做法,讓我們的化合物也能在其他情境中被納入考量。
With regard to the second question, which is ivonescimab and how will we make decisions about when to advance into a late-stage trial, probably the same way we make all such decisions. So it will be data driven. It will depend on the context. Potentially, this class of inhibitors could offer a significant advantage over the first-generation PD-1 inhibitors.
至於第二個問題,也就是 ivonescimab,以及我們會如何決定何時推進到後期試驗,我想大概會和我們做所有此類決策的方式一樣。也就是以數據為驅動。並且取決於具體情境。這一類抑制劑可能相較於第一代 PD-1 抑制劑提供顯著優勢。
There is growing body of evidence to support that. We don't have the definitive data yet, and we are staying very much on the front lines of a combination of strategies involving ivo with our RAS(ON) inhibitors. So I think we'll be in a great position to make the decision with some data in hand.
支持這一點的證據正在累積。我們目前還沒有決定性的數據,但我們正非常積極地站在前線,推進以 ivo 與我們的 RAS(ON) 抑制劑所組成的多種聯合策略。因此我認為,當我們手上有一些數據時,將會處於很好的位置來做出決策。
Charles Zhu - Equity Analyst
Charles Zhu - Equity Analyst
Understood. Thanks for taking the questions.
了解。謝謝回答問題。
Operator
Operator
Marc Frahm, TD Cowen.
Marc Frahm,TD Cowen。
Marc Frahm - Analyst
Marc Frahm - Analyst
Thanks for taking my question. Congrats on all the progress. Maybe just first off on more of a bit of a housekeeping. Can you just confirm whether any event thresholds have been reached in 302 to trigger interim analyses yet or if just none of those have been hit yet?
謝謝讓我提問。恭喜你們取得所有進展。先從比較偏行政/例行事項的問題開始。你們能否確認 302 是否已達到任何事件門檻(event thresholds)以觸發期中分析?還是目前都尚未達到?
And then thinking more broadly about pancreatic cancer, now you have several first-line trials either ongoing or getting started in the next handful of months. Just what is the kind of long-term vision you have for what the treatment paradigm in pancreatic cancer looks like in four or five years? How do daraxonrasib, zoldonrasib, chemo all get sequenced for maybe the typical patients?
接著更廣泛地談胰臟癌:你們現在有數個一線試驗正在進行,或將在接下來幾個月內啟動。你們對於四到五年後胰臟癌治療典範的長期願景是什麼?對於一般患者而言,daraxonrasib、zoldonrasib、化療等會如何排序與銜接使用?
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Thanks for your question, Marc. I think I'll comment on the first one, and then maybe Alan Sandler can comment on your question about sort of future landscape and future expectations for treatment paradigms.
謝謝你的問題,Marc。我先回應第一個問題,然後也許 Alan Sandler 可以回應你關於未來格局與治療典範預期的問題。
My comment is, I don't really have any answer to your question. When the data are unblinded, that causes us to do an analysis, which then leads to a disclosure. And that's about all I can say to that. On your question about how does pancreatic cancer look a few years from now, Alan?
我的回應是,我其實沒有辦法回答你的問題。當數據解盲(unblinded)時,我們就會進行分析,接著才會做出揭露。我對此大概只能說到這裡。至於你問的幾年後胰臟癌會是什麼樣子,Alan?
Alan Sandler - Chief Development Officer
Alan Sandler - Chief Development Officer
Thanks for the question. Well, I think we're -- we've set up very nicely with multiple studies to have a major say to what's pancreatic cancer will look like in the next three to five years, with our early studies looking at second-line therapy with daraxonrasib moving into the first-line setting, also with daraxonrasib looking at it both with respect to monotherapy but also potentially in combination with chemotherapy.
謝謝你的問題。我認為我們透過多項研究的布局非常到位,將能在未來三到五年對胰臟癌的樣貌有重要發言權;我們的早期研究先從 daraxonrasib 的二線治療著手,並推進到一線治療場景,同時也以 daraxonrasib 分別評估單藥治療,以及可能與化療聯合的方式。
And then we're doing that with a more specific agent such as zoldonrasib for G12D and looking at that as well in combination with chemotherapy versus chemotherapy in the frontline setting, but also the novel ability to combine it with daraxonrasib also in that first-line setting.
此外,我們也以更具特異性的藥物(例如針對 G12D 的 zoldonrasib)進行同樣的策略,評估其在一線治療中與化療聯合對比化療;同時也具備一項新穎能力:在一線治療中將其與 daraxonrasib 聯合。
This will provide patients with the optionality in first-line setting to actually potentially have a chemotherapy-free opportunity, as well as building upon the results that have been seen with chemotherapy alone. In addition, and potentially even more importantly, we have the opportunity to impact patients who have potentially curable pancreatic cancer by conducting 304, which is our adjuvant study for those patients who have had resected cancer in perioperative therapy.
這將讓患者在一線治療中具備選擇性,實際上可能有機會採取無化療(chemotherapy-free)的方案,同時也能在僅用化療所見到的結果之上再加以提升。此外,且可能更重要的是,我們也有機會影響那些可能可治癒的胰臟癌患者:透過進行 304(我們的輔助治療研究),針對已在圍手術期治療後完成腫瘤切除的患者。
So we really are covering the gamut of patients of pancreatic cancer from second-line therapy all the way to resectable and potentially curable pancreatic cancer. And I think that covers probably three to five and maybe even a year or two beyond that as well. And then in addition, of course, as Mark mentioned earlier, there are other agents in our pipeline that we'll be looking at as well that will also potentially have an impact.
因此,我們確實涵蓋了胰臟癌患者的完整光譜,從二線治療一路到可切除、且可能治癒的胰臟癌。我認為這大概涵蓋了三到五年,甚至可能再往後延伸一到兩年。此外,當然如 Mark 先前提到的,我們的研發管線中還有其他藥物也會一併評估,這些也可能帶來影響。
Marc Frahm - Analyst
Marc Frahm - Analyst
Okay, thank you.
好的,謝謝。
Operator
Operator
Alec Stranahan, Bank of America.
Alec Stranahan,美國銀行。
Alec Stranahan - Analyst
Alec Stranahan - Analyst
Hey, guys. Thanks for taking our questions. With the ivonescimab study now dosing patients, I guess, could you maybe speak a bit about the study design and which tumor types and lines of therapy you expect might enrich in the study as it enrolls? And longer term, how is this combo maybe emblematic of how you're hedging your RAS therapies alongside potential shifts in standard of care? Thank you.
嗨,各位。謝謝回答我們的問題。目前 ivonescimab 研究已開始對患者給藥,我想請你們談談研究設計,以及在收案過程中,你們預期哪些腫瘤類型與治療線別可能會在研究中被富集?另外從長期來看,這個組合是否可視為你們在標準治療可能轉變的情況下,如何同時布局/對沖 RAS 治療策略的一個代表性例子?謝謝。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Thanks, Alex (sic - Alec). I think Dr. Lin, our Chief Medical Officer, can comment on what's our approach to ivo in the initial Phase 1 context.
謝謝你,Alex(原音 - Alec)。我想林醫師,我們的首席醫療官,可以就 ivo 在初始第一期情境下的策略作說明。
Wei Lin - Chief Medical Officer
Wei Lin - Chief Medical Officer
Thanks for the question. So the trial, as has been pointed out, has been initiated, and that's the APEX study. It involved all three kind of stage RAS(ON) inhibitors. That's daraxonrasib, zoldonrasib, as well as elironrasib that covers all RAS, the G12D as well as the G12C population.
謝謝你的提問。如先前所提到,該試驗已啟動,也就是 APEX 研究。它涵蓋了三種不同階段的 RAS(ON) 抑制劑。包括 daraxonrasib、zoldonrasib,以及 elironrasib,涵蓋所有 RAS,也涵蓋 G12D 以及 G12C 族群。
There's a standard dose escalation involving ivonescimab in combination with daraxonrasib, in combination zoldon, and in combination with elironrasib. And the dose escalation is standard all solid tumors and will be helped to define the safety and preliminary activity across some major solid tumors that's going to be seen.
這是一個標準的劑量遞增設計,使用 ivonescimab 分別與 daraxonrasib 聯合、與 zoldon 聯合,以及與 elironrasib 聯合。劑量遞增部分為標準的全實體腫瘤設計,將有助於界定安全性,並初步評估在一些主要實體腫瘤中的活性。
And then once the dose has been defined and safety has been cleared, there is dedicated expansion cohort across the three major diseases of interest both Summit as well Revolution Medicine's side. And it really is focusing on the three diseases that we have focused on today. That include pancreatic cancer, non-small cell lung cancer, and colorectal cancer.
接著在劑量確定且安全性獲得確認後,會針對我們與 Summit 以及 Revolution Medicine 共同關注的三大疾病,設置專門的擴增隊列。也就是我們今天聚焦的三個疾病領域。包括胰臟癌、非小細胞肺癌,以及大腸直腸癌。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
And with -- do you want to repeat your second question, which has to do with, I guess, hedging how treatment landscape may evolve in the context of ivo?
至於——你要不要再重述一下你的第二個問題?我想是關於在 ivo 的情境下,如何對沖治療版圖可能的演變?
Alec Stranahan - Analyst
Alec Stranahan - Analyst
Yes, just broadly, how you're thinking about combos as standard of care across these treatment setting?
是的,概括來說,你們如何看待在這些治療場景中,聯合療法成為標準治療的可能性?
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Yeah. Well, I think we're not holding anything up. We're certainly developing things in combination with pembro to the extent that that makes sense to do. But we also have to recognize that field is evolving. And so we're right on the leading edge of it in collaboration with Summit to make sure that we're the first to evaluate RAS inhibitors and particularly class-leading RAS(ON) inhibitors in combination with ivo. And we'll learn a lot.
是的。我想我們並沒有把任何事情擱置。在合理的情況下,我們當然也在推進與 pembro 的聯合開發。但我們也必須認知到這個領域正在演進。因此我們與 Summit 合作、站在最前沿,確保我們能率先評估 RAS 抑制劑,尤其是同類最佳的 RAS(ON) 抑制劑,與 ivo 的聯合。我們也會從中學到很多。
With regard to non-small cell lung cancer, where pembro really is a dominant standard of care in most parts of the world, it will take more to knock that off and for that -- for there to be a real change. And that will be up to ivo to prove itself, which is currently -- work that's underway. In the GI tumors, there's much less of a precedent here. And the combination of a PD-1 and a VEGF inhibitor in the same molecule really opens up a real significant opportunity there.
就非小細胞肺癌而言,pembro 在全球多數地區確實是主導性的標準治療,要撼動它、要出現真正的改變,需要更多證據。這將取決於 ivo 是否能證明自身價值;目前相關工作正在進行中。在腸胃道腫瘤方面,這方面的先例要少得多。而把 PD-1 與 VEGF 抑制作用整合在同一個分子中的組合,確實在那裡開啟了非常顯著的機會。
And again, to be the first RAS inhibitors for the [RAS-meeting] versions of those tumors in combination with ivo is an exciting thing to do. So we're playing all the time sort of like our overall strategy, everything everywhere all at once. And that's pretty much what we have to do in a rapidly evolving environment.
同樣地,能夠率先在這些腫瘤的 [RAS-meeting] 版本中,將 RAS 抑制劑與 ivo 聯合,是一件令人振奮的事。所以我們的整體策略有點像是:任何時間、任何地方、同時推進所有事情。在快速演變的環境中,這基本上就是我們必須做的。
Alec Stranahan - Analyst
Alec Stranahan - Analyst
That makes sense. Thanks so much for the color.
了解。非常感謝補充說明。
Operator
Operator
Asthika Goonewardene, Truist.
Asthika Goonewardene,Truist。
Asthika Goonewardene - Analyst
Asthika Goonewardene - Analyst
Hey, guys. Thanks for taking my question. I want to kind of go back to Albert's question at the beginning, specifically, on daraxonrasib and frontline non-small cell lung (technical difficulty). I guess, in previous calls -- earnings calls, we've talked about -- and you pointed out how pembro plus chemo is a backbone therapy and how it makes a lot of sense to consider that in combination with daraxonrasib.
嗨,各位。謝謝回答我的問題。我想回到一開始 Albert 的問題,特別是關於 daraxonrasib 與一線非小細胞肺癌(技術問題)。我想在之前的電話會議——財報電話會議中,我們談到過——你們也指出 pembro 加化療是基礎治療(backbone therapy),而把它與 daraxonrasib 聯合是很合理的。
But when you talked about other options today -- I wanted to just get a little clarity here. When you talk about other options, do you mean other PD-1s in combination with chemo? Are there mechanisms like maybe involving PD-1 and CTLA-4? Or are you thinking -- are you considering chemo-free options here for the ideal regimen you want to take daraxon into frontline non-small cell lung?
但你們今天提到其他選項時——我想在這裡釐清一下。你們所說的其他選項,是指其他 PD-1 與化療的聯合嗎?是否也包含像 PD-1 與 CTLA-4 相關的機制?或者你們在思考——是否在考慮無化療(chemo-free)的選項,作為你們希望把 daraxon 帶入一線非小細胞肺癌的理想療程?
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
I think that was really in reference to first-line lung daraxonrasib and whether it should be combined with pembro and chemo, or whether potentially ivo emerges during that period of time. I think that was the context for that narrow answer that we're now evaluating ivo, and so we'll have some of that information.
我想那其實是針對一線肺癌的 daraxonrasib:它是否應該與 pembro 及化療聯合,或是在那段期間 ivo 可能會成為新的選項。我想那就是當時那個較為聚焦的回答脈絡:我們現在正在評估 ivo,因此之後會有一些相關資訊。
But in the meantime, as Steve had articulated, we are doing -- continuing the dose optimization and efficacy analysis of daraxon plus pembro plus chemo, the KEYNOTE-189 context. So those are running in parallel, and that will put us in a good position to make the best decision.
但同時,如 Steve 所闡述的,我們正在進行——並將持續進行 daraxon 加 pembro 加化療的劑量最佳化與療效分析,也就是 KEYNOTE-189 的情境。因此這兩條路徑是並行推進的,這會讓我們處於良好位置,做出最佳決策。
Asthika Goonewardene - Analyst
Asthika Goonewardene - Analyst
Got it. Thank you. If I can sneak a quick one in, any thoughts on whether you would use your commissions prior to review voucher for second-line PDAC when we had the RASolute 302 data in hand? Thanks, guys.
了解。謝謝。如果我可以再快速追問一個:當我們拿到 RASolute 302 的數據後,你們是否會考慮在二線 PDAC 使用你們的 commissions prior to review voucher?謝謝,各位。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Thank you. What's the question?
謝謝。請問問題是什麼?
Ryan Asay - Senior Vice President of Corporate Affairs
Ryan Asay - Senior Vice President of Corporate Affairs
CNPV will be used for second-line PDAC?
CNPV 會用於二線 PDAC 嗎?
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
I see. Yeah, I think that's been made clear that it wouldn't really make sense to hold back. The CNPV was awarded on the basis of largely second-line and third-line data that we have shown publicly and shared with the FDA. And so I can't really see a scenario in which we wouldn't be operating under the CNPV in that second-line 302 data readout context.
我了解。是的,我想我們已經說得很清楚,沒有太大理由要保留不用。CNPV 的核發基礎,主要是我們已公開展示、並與 FDA 分享的二線與三線數據。因此我很難想像在二線 302 數據讀出時,我們不會在 CNPV 的框架下運作。
Operator
Operator
Laura Prendergast, Stifel.
Laura Prendergast,Stifel。
Laura Prendergast - Equity Analyst
Laura Prendergast - Equity Analyst
Hey, guys, thanks for taking the question. In a recent public appearance, Mark, you brought up the concept of treating beyond progression in PDAC from the angle of patients progressing under daraxonrasib and (technical difficulty) amplification of the RAS target.
嗨,各位,謝謝回答問題。在最近一次公開露面中,Mark,你提到在 PDAC 中「進展後仍持續治療」(treating beyond progression)的概念,從患者在 daraxonrasib 治療下出現進展,以及(技術問題)RAS 標的擴增的角度來談。
Considering a pretty unique consideration in oncology where (technical difficulty) the drug upon progression of PDAC (technical difficulty) in the patients, (technical difficulty) you go for some questions at our end. First, our investigators on the Phase 3 studies, the first-and second-line PDAC be encouraged (technical difficulty) is allowed for any protocols and you (technical difficulty) --
考量到腫瘤科中一個相當獨特的情況,也就是在 PDAC 進展後(技術問題)患者使用該藥物(技術問題),(技術問題)我們這邊有一些問題想請教。首先,我們在第 3 期研究中的研究者,對於一線與二線 PDAC 是否應被鼓勵(技術問題)在任何方案中允許,以及你們(技術問題)--
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Since I could only hear every other word you're saying, I'm going to have to sort of infer the question was about treatment beyond progression. We have made the comment that we've heard a number of anecdotes from investigators who have chosen to continue treating patients based on clinical criteria, even in the face of some sort of radiographic progression.
由於我只能聽清楚你說的每隔幾個字,我得大概推測你的問題是在問「疾病進展後是否仍繼續治療」。我們曾提到,我們從多位研究者那裡聽到一些個案經驗:即使影像學顯示某種程度的進展,他們仍基於臨床判準選擇繼續治療病人。
And in that context, they've observed a number of patients who continue to do quite well on daraxonrasib for even long periods of time. And the biological context for that is that RAS doesn't disappear as a driver. It's the driver before we treat with a RAS inhibitor. It's the driver while we're treating with the RAS inhibitor. And it's a driver after you stop treating with a RAS inhibitor.
在那樣的情境下,他們觀察到有不少病人即使在相當長的一段時間內,使用 daraxonrasib 仍持續表現得很好。其背後的生物學脈絡在於,RAS 作為驅動因子並不會消失。在我們用 RAS 抑制劑治療之前,它是驅動因子。在我們用 RAS 抑制劑治療期間,它也是驅動因子。而在你停止使用 RAS 抑制劑之後,它仍然是驅動因子。
And so in reality, probably doesn't make much sense to discontinue if a patient is continuing to benefit, and that set of observations that we've heard syncs up nicely with that underlying biology. So -- but we don't have enough quantitative data to really say anything definitively. We're really giving you anecdotal comments here and theoretical comments.
因此,若病人仍持續受益,實際上停止治療可能並不太合理;而我們聽到的那一組觀察結果,也與上述基礎生物學相當吻合。不過——我們沒有足夠的量化數據,無法做出任何明確的結論。我們在這裡提供的主要是個案性的評論與理論性的看法。
But now we'd like to collect some more data to determine if that really does establish an additional benefit over and above the benefit they've already received at that point in time. That's my general comments, but I don't know what the actual question was. Can you clarify what you were specifically asking beyond that?
但接下來我們希望蒐集更多數據,以判斷這樣做是否真的能在當時病人已獲得的效益之上,建立額外的好處。以上是我概括性的評論,但我不確定你原本的實際問題是什麼。你能否釐清一下,你具體想問的是哪些點?
Laura Prendergast - Equity Analyst
Laura Prendergast - Equity Analyst
Yeah. So specifically, as it relates to study protocols, was there any restrictions on how much -- on whether or not this is a possibility on the first-line or second-line Phase 3? And then how you guys think this could impact overall survival of those studies?
好的。具體來說,就研究方案而言,一線或二線的第 3 期試驗,對於「是否可能」以及「允許到什麼程度」有沒有任何限制?另外,你們認為這可能會如何影響那些研究的整體存活期(OS)?
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Yeah. Okay. I do understand the question now. So did we formalize this in the 302 study versus other studies? It's not in the 302 study because that study was already too far underway to make that modification. That would be difficult to do in the middle of the study.
是的。好的。我現在理解問題了。也就是說,我們是否在 302 研究中把這件事正式納入,或是在其他研究中納入?302 研究沒有納入,因為該研究在當時已進行到相當後期,無法再做這樣的修改。在研究進行到一半時要做調整會很困難。
And so progression beyond -- treatment beyond progression was not permitted, is not permitted in the 302 study. But as other studies come online, we've encouraged investigators to evaluate that possibility and where it makes sense to continue treatment beyond progression, particularly in the earlier-line studies. And so we'll be able to generate a lot more information in those contexts.
因此,在 302 研究中,「進展後仍繼續治療」是不被允許的,目前也仍不允許。但隨著其他研究陸續啟動,我們已鼓勵研究者評估這種可能性;在合理的情況下,特別是在較前線治療的研究中,於進展後繼續治療。因此,我們將能在那些情境下產生更多資訊。
Laura Prendergast - Equity Analyst
Laura Prendergast - Equity Analyst
Got it. Thank you.
了解。謝謝。
Operator
Operator
Jay Olson, Oppenheimer.
Jay Olson,Oppenheimer。
Jay Olson - Analyst
Jay Olson - Analyst
Hey, guys. Congrats on all the progress. Thanks for taking our question. Since you're making a lot of headway in PDAC and non-small cell lung cancer, can you talk about your vision and strategy in colorectal cancer? And how are you prioritizing the CRC opportunity for RevMed?
嗨,各位。恭喜你們取得所有進展。謝謝你們回答我們的問題。既然你們在 PDAC 與非小細胞肺癌方面都有很大進展,能否談談你們在大腸直腸癌(CRC)上的願景與策略?以及你們如何為 RevMed 排定 CRC 機會的優先順序?
Is CRC an area that you would prefer to focus on with partnerships, for example, in combination with ivonescimab? Or is CRC something that you plan to pursue independently? And from a BD perspective, would you consider in-licensing some molecules that have synergy with your RAS portfolio so you wouldn't need to rely on partnerships in CRC? Thank you.
CRC 是否是你們更希望透過合作夥伴來聚焦的領域,例如與 ivonescimab 的聯合治療?或者 CRC 是你們計畫自行推進的領域?另外從 BD(商務拓展)的角度,你們是否會考慮引進授權(in-licensing)一些與你們 RAS 產品組合具有協同效應的分子,讓你們在 CRC 上不必依賴合作夥伴?謝謝。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Yeah, Jay, thanks for your question. Maybe Steve Kelsey can just comment in general on our approach to CRC. And then if there's anything left on BD at the end, I can come back and comment on it.
好的,Jay,謝謝你的提問。也許先請 Steve Kelsey 先就我們對 CRC 的整體做法做一些評論。如果最後還有 BD 相關的部分,我再補充說明。
Steve Kelsey - President - Research and Development
Steve Kelsey - President - Research and Development
Yeah. I mean, colorectal cancer has never been deprioritized. We -- from -- right from the very first -- right from the start of the daraxon -- RAS(ON) [and overall] dose escalation studies, we included patients with colorectal cancer.
好的。我的意思是,大腸直腸癌從來沒有被降低優先順序。我們——從一開始——從 daraxon——RAS(ON)(以及整體)劑量遞增研究一開始,我們就納入了大腸直腸癌患者。
I think what we found, which was hardly surprising because a number of other people have also found this both for and since is the colorectal cancer is an incredibly complex and heterogeneous disease with multiple subclones. Each of those clones often containing multiple genetic abnormalities.
我想我們發現的事情其實並不令人意外,因為許多其他人之前與之後也都發現:大腸直腸癌是一種極其複雜且高度異質性的疾病,具有多個亞克隆。而每個克隆往往又包含多種基因異常。
And as a result, what happens is that -- two things happened really. One is the overall response rates are lower than they are traditionally in the other RAS-driven diseases, which makes rapid decision-making of our future clinical development more complicated because you have now you have to wait for somewhat longer-term readouts like PFS.
因此,實際上會發生——主要有兩件事。第一,整體反應率比其他傳統由 RAS 驅動的疾病要低,這使得我們對未來臨床開發做快速決策更為複雜,因為你現在必須等待較長期的讀出,例如無惡化存活期(PFS)。
And secondly, it's an obligatory -- when it comes on combination play, you really -- there really are no opportunities for developing a single agent in advanced colorectal cancer. In the late-stage colorectal cancer after chemotherapy failed, it's such a heterogeneous and genetically complex disease unique combinations.
第二,當談到聯合治療策略時,這幾乎是必然的——在晚期大腸直腸癌中,基本上沒有開發單一藥物(單藥)治療的機會。在化療失敗後的晚期大腸直腸癌中,它是如此異質且基因層面如此複雜,以致需要特定且獨特的組合。
And in earlier lines of therapy, you really need to combine with combination chemotherapy, which is standard of care. So it becomes more difficult and more time-consuming to reach a point where there's a clear path forward into pivotal trials. And I think that's what we have found, and it's got nothing to do with prioritization. It's got -- it's really down to the biology of the disease and how that translates into early-stage clinical trials.
而在較前線的治療中,你確實需要與標準治療(SOC)的聯合化療併用。因此,要走到一個能清楚看見通往關鍵性試驗(pivotal trials)路徑的時間點,就會更困難也更耗時。我想這就是我們的發現,而這與優先順序無關。這其實取決於疾病的生物學,以及它如何轉化到早期臨床試驗的結果。
And with regards to methodology, I mean, our philosophy as a company is that we have made the decision to be a standalone global organization. And we are not looking to change that really based on disease or histotype.
至於方法論方面,我們公司的理念是:我們已決定成為一家獨立運作的全球性組織。我們並不打算因為疾病領域或組織學亞型而改變這一點。
There may be opportunities for doing studies in collaboration with partners if the right partner -- if we believe that's the right combination and we have the right partner, we may choose to do with -- as part of a clinical collaboration or maybe even as some other type of business arrangement.
如果我們認為某些研究有機會與合作夥伴共同進行——也就是我們相信那是正確的組合,且有合適的合作夥伴——我們可能會選擇以臨床合作的方式進行,或甚至採取其他類型的商業安排。
But right now, that's not the preferred or even the base case plan. Our plan is to figure out which combinations involving a RAS(ON) inhibitor can make the biggest impact on colorectal cancer and prosecute those to registration.
但就目前而言,這既不是我們偏好的做法,甚至也不是基本情境(base case)的計畫。我們的計畫是找出哪些包含 RAS(ON) 抑制劑的組合,能對大腸直腸癌產生最大的影響,並推進到註冊申請(registration)。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
I think your answer covered it pretty darn well. Maybe the one last little piece is, would we bring in additional compounds into our pipeline. And that's always possible. We have a very robust process by which we evaluate other people's assets.
我覺得你的回答已經涵蓋得非常完整了。也許最後再補充一點:我們是否會把其他化合物納入我們的產品線。這永遠是有可能的。我們有一套非常健全的流程,用來評估其他公司的資產。
We receive a lot of inbound proposals. And occasionally, we reach out to somebody else to look to learn more. So that's all just the practical considerations. The fundamental points I think Steve made are the fundamental points.
我們收到很多主動提案(inbound proposals)。而且有時候,我們也會主動聯繫其他人,以便進一步了解。所以這些都是實務上的考量。我認為 Steve 所說的那些基本點,才是最根本的重點。
Operator
Operator
Leo Timashev, RBC.
Leo Timashev,RBC。
Leonid Timashev - Equity Analyst
Leonid Timashev - Equity Analyst
Thanks for taking my question. I wanted to ask a little bit on RM-055 in that class of molecules. I guess, does this address secondary mutations? Or does it really only work directly on RAS mutations themselves? And I guess, said another way, do you think you'll ultimately need to be selecting patients that might be amenable to this?
感謝讓我提問。我想就 RM-055 這一類分子再多問一點。我想確認一下,這是否能處理次級突變?還是它其實只會直接作用在 RAS 突變本身?換句話說,您認為最終是否需要篩選那些可能適用於此療法的病人?
And then just based on some of the preclinical work you've shown, it looks like it drives a very deep responses even relative to daraxonrasib. So are you seeing this ultimately be positioned as a next line option? Or can this be something that ultimately replaces and is a better daraxonrasib? Thanks.
另外,根據你們展示的一些臨床前工作,看起來它能帶來非常深度的反應,甚至相較於 daraxonrasib 也是如此。所以你們是否認為它最終會被定位為下一線的選擇?或者它是否可能最終取代 daraxonrasib,成為更好的 daraxonrasib?謝謝。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Yeah. Thanks, Leo. Appreciate the question. All interesting ideas. I think that will become a little bit clearer when our scientific team has a chance to present more formally and in a more fulsome way at an upcoming scientific meeting.
是的。謝謝你,Leo。感謝你的提問。都是很有意思的想法。我想等我們的科學團隊有機會在即將到來的科學會議上,以更正式、也更完整的方式進行發表時,這些問題會更清楚一些。
The one thing I'll say biologically is that point mutations have not emerged as the major form of resistance for daraxonrasib. What has emerged is reactivation of the RAS pathway through other means, typically amplification of the original mutant allele through increased signaling, for example, through RTKs to increase flux through the pathway and so on.
我唯一想從生物學角度補充的是:點突變並未成為 daraxonrasib 的主要抗藥機制。目前看到的是透過其他方式使 RAS 路徑再活化,通常是原始突變等位基因的擴增,藉由訊號增強,例如透過 RTKs 增加路徑中的通量等等。
And so daraxonrasib seems to do generally a very good job of suppressing new oncogenic mutations that might have otherwise emerged in the [setting] of a selective -- mutant-selective inhibitor. So that really isn't the primary problem that we're trying to address or that the team had as its mission in developing this new class of inhibitors. But more to come. Stay tuned. Thanks for the question.
因此,daraxonrasib 似乎整體而言非常擅長抑制那些在選擇壓力下——也就是突變選擇性抑制劑的情境中——原本可能會出現的新致癌突變。所以這並不是我們試圖解決的主要問題,也不是團隊在開發這一新類別抑制劑時的核心任務。不過後續還會有更多資訊。敬請期待。謝謝你的提問。
Operator
Operator
Ami Fadia, Needham & Company.
Ami Fadia,Needham & Company。
Unidentified Participant
Unidentified Participant
Hi, this is [Poorna], on for Ami. Thank you for taking our question. Just wanted to understand how soon can you get to commercialization of data in case the first interim is positive? What are some of the aspects within the commercialization preparations that you still need to work through? Thank you.
你好,我是 [Poorna],代替 Ami 提問。感謝讓我們提問。我想了解的是:如果第一次期中分析結果是正面的,你們最快多久可以推進到商業化?在商業化準備方面,還有哪些環節是你們仍需要進一步完成的?謝謝。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Thank you for those questions. So I think you're asking about what if we don't repair and what does the timeline look like? I think Anthony can step into that.
謝謝這些問題。所以我想你問的是:如果我們不需要修正,那時間表會是什麼樣子?我想 Anthony 可以來回答。
Anthony Mancini - Chief Global Commercialization Officer
Anthony Mancini - Chief Global Commercialization Officer
Yeah. Thanks for the question. I think we're really pleased with how our launch ready as planned. We are advancing and we continue to add highly experienced and talented members of the team. And we're really achieving broad organizational readiness led by the US, but also in Europe and in Japan. So we're really pleased with the launch readiness across the board.
好的。謝謝你的問題。我認為我們對於按計畫達成上市準備就緒(launch ready)的進展感到非常滿意。我們正在推進,也持續延攬具備高度經驗與才華的團隊成員。我們也正在達成廣泛的組織就緒度,由美國主導,同時也涵蓋歐洲與日本。因此,我們對於整體的上市準備狀況都非常滿意。
As Mark alluded to in his prepared remarks, that launch readiness in terms of the US, the first launch is actually proceeding quite well with leadership teams in place across commercialization and cross functions field-based leaders across med affairs, market access, marketing and sales.
正如 Mark 在事先準備的發言中提到的,就美國而言,首次上市在準備上其實進展得相當順利;商業化與跨職能的領導團隊已到位,包含醫藥事務、市場准入、行銷與銷售等各領域的外勤(field-based)主管。
And as Mark mentioned as well, we've now initiated the posting of our further extension of our field-based teams, our sales team. So we're really, really pleased with how the launch readiness overall is coming together. And certainly, as we get closer to filing and launch, we'll provide some more color there.
而且如 Mark 也提到的,我們現在已開始發布職缺,進一步擴充我們的外勤團隊,也就是銷售團隊。所以我們對於整體上市準備的整合進展感到非常、非常滿意。當然,隨著我們更接近申報與上市,我們也會提供更多細節。
Operator
Operator
Kalpit Patel, Wolfe Research.
Kalpit Patel,Wolfe Research。
Kalpit Patel - Analyst
Kalpit Patel - Analyst
Yeah, hey, thanks for taking the question. I guess, how should we think about the disclosure of the pivotal update here in second-line pancreatic. If for any reason, you missed the interim PFS analysis and that does not cross the prespecified boundary, would you expect to provide an update at that point? Or would you just wait for the OS-driven readout after?
是的,嗨,謝謝讓我提問。我想問的是,我們應該如何看待這裡在二線胰臟癌的關鍵性更新之揭露方式?如果因為任何原因,你們錯過了期中 PFS 分析,而且沒有跨越預先設定的界值,你們會預期在那個時間點提供更新嗎?還是會等到之後以 OS 驅動的讀出結果?
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Well, thanks for your question. I don't think we can give you much of an answer to that question right now. We'll see what the data show and decide what we consider as appropriate disclosure at that time. Just a reminder, it's OS event-driven. It's powered for OS, which means it's more powered for PFS.
嗯,謝謝你的問題。我想我們現在還無法就這個問題給你太多答案。我們會先看數據顯示什麼,再決定當時我們認為適當的揭露方式。提醒一下,這是以 OS 事件驅動(event-driven)。研究的統計把握度(power)是為 OS 設計的,這也意味著對 PFS 的把握度更高。
So the possibility that it doesn't cross PFS is less likely than not crossing OS at that interim analysis. So if there's a split result, it could be PFS has crossed and OS has not reached statistical significance yet. That's conceivable. Not emphasizing that, particularly, but it is one of the possible scenarios. And we'll just have to see what that looks like at that point in time and make an appropriate disclosure decision.
因此,在那次期中分析時,PFS 沒有跨越界值的可能性,相較於 OS 沒有跨越界值的可能性要低。所以如果出現分歧結果,有可能是 PFS 已跨越,而 OS 尚未達到統計顯著性。這是可以想像的。我不是特別強調這一點,但它確實是可能情境之一。我們只能等到那個時間點看看結果長什麼樣,再做出適當的揭露決策。
Kalpit Patel - Analyst
Kalpit Patel - Analyst
Thank you.
謝謝。
Operator
Operator
Sean McCutcheon, Raymond James.
Sean McCutcheon,Raymond James。
Sean McCutcheon - Analyst
Sean McCutcheon - Analyst
Hey, guys, thanks for the questions. Can you speak to the staggering of enrollment for RASolute 302, 305 and 309, and the 303 protocol components to ensure a representative sample of mutations in 303 and avoid an enrichment of non-G12D patients?
嗨,各位,謝謝回答問題。你們能否談談 RASolute 302、305 與 309 的入組節奏安排(staggering of enrollment),以及 303 試驗方案(protocol)的組成要素,如何確保 303 中突變型別具有代表性的樣本,並避免非 G12D 病人的富集?
And perhaps, germane to that as well, can you speak to your expectation for the G12D versus G12V and G12R patients, and the GNP arm given G12D tends to be a bit more aggressive and chemo-resistant? Thanks.
另外,與此也相關的是,鑑於 G12D 往往更具侵襲性且對化療較具抗性,你們能否談談對 G12D 相較於 G12V 與 G12R 病人的預期,以及在 GNP 組別的預期?謝謝。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Okay, I got the general idea. There were a lot of specifics in that, maybe just the staggering of enrollment. Just to make sure we understood your question, were you linking the staggering of enrollment to the mutation representation? Or was that more of a broad question about getting access to patients and enrolling patients? I didn't quite follow that.
好的,我大致理解你的意思。你剛剛提到很多細節,可能先聚焦在入組節奏安排這部分。為了確保我們理解你的問題,你是把入組節奏安排與突變代表性連結在一起嗎?還是那其實是更廣泛、關於如何接觸病人並完成入組的問題?我沒有完全跟上。
Sean McCutcheon - Analyst
Sean McCutcheon - Analyst
Yeah, linking. So obviously, 303 is all-comers there versus 305, 309 being G12D. So the staggering as it relates to kind of shuttling the patients -- avoiding shuttling the G12D patients to the 305 and 309 studies.
是的,是連結在一起。所以很明顯,303 是全收案(all-comers),而 305、309 則是 G12D。因此,入組節奏安排是關於如何在病人之間做分流——避免把 G12D 病人分流到 305 與 309 研究中。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Do you want to comment on that?
你想評論一下嗎?
Wei Lin - Chief Medical Officer
Wei Lin - Chief Medical Officer
Sure. I think some of this will be managed by the site selection, all three global trials. We're certainly mindful that we want to have a fair and equitable representation of RAS mutant in the RAS all-comer population in the 303 study and the G12D mutant population in 305 as well as 309.
當然。我認為其中一部分會透過試驗中心(site)選擇來管理,這三項都是全球性試驗。我們當然也很留意:在 303 研究的 RAS 全收案族群中,要讓 RAS 突變有公平且均衡的代表性;同時在 305 與 309 中,也要讓 G12D 突變族群有適當代表性。
And the control arm do vary among these three trials. So 305 specifically does offer both GMP as well as FOLFIRINOX versus 309 and 303 offers GMP as a control. So -- and as you know, there are local regional practices as well as consumer practices when it comes to preference for GMP and FOLFIRINOX.
而且這三項試驗的對照組確實不同。305 特別提供 GMP 以及 FOLFIRINOX 作為對照;相較之下,309 與 303 則提供 GMP 作為對照。所以——如你所知,在偏好 GMP 或 FOLFIRINOX 方面,也存在各地區的在地醫療實務,以及病人端的偏好。
So we have a variety of sites, region, country to select from. The PDAC patients are certainly -- they are very common. As you know, there's about nearly 60,000 Americans with PDAC every year. Half of those are probably -- first-line metastatic patients in US alone would account for about 30,000 in a year. And globally, certainly many more.
所以我們有各式各樣的試驗中心可選,涵蓋地區與國家。PDAC 病患當然——相當常見。如各位所知,美國每年約有將近 60,000 名 PDAC 病患。其中一半可能——僅就美國而言,一線轉移性病患一年大約就有 30,000 名。而在全球,當然還要多得多。
So I don't think there'll be a lack of patients they'll be selecting from. It's really trying to identify sites based on their local factors and investor interest in any of these trials and then offering these trials as option to their patients. So -- and we're certainly mindful about the site footprint overlap around these three studies to ensure that there's a -- the competition across these three studies are not going to be at individual site level.
所以我不認為會缺乏可供納入的病患來源。真正要做的是根據各中心的在地因素,以及投資人對這些試驗的關注度來辨識試驗中心,並將這些試驗作為選項提供給其病患。所以——我們也確實留意這三項研究在試驗中心佈局上的重疊,以確保這三項研究之間的競爭不會發生在單一試驗中心層級。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Maybe that mutational -- mutations in their representation, 85% of PDAC cases have a G12 mutation. Things could be hard to bias that dramatically just from a few ongoing trials. And so there should be fairly similar representation across any of the multi-RAS inhibitor trials. And then in a G12D trial, it's going to be G12D mutation is going to be very specific for that.
也許就突變——在其代表性方面,85% 的 PDAC 病例具有 G12 突變。僅靠少數正在進行的試驗,要把這個比例大幅偏移可能很難。因此,在任何多重 RAS 抑制劑試驗之間,代表性應該會相當類似。而在 G12D 試驗中,則會非常特定地聚焦於 G12D 突變。
And then within any given trial, there should be balance between the control groups and the treatment groups. Because there will be randomization after patients designated for particular chemo type. If it's a chemo-bearing trial, then they would be randomized to treatment arm versus chemo. So this should be balanced throughout these. I'm not sure that there's any inherent bias that would lead towards anything unusual.
此外,在任何特定試驗內,對照組與治療組之間應該會保持平衡。因為在病患被指定特定化療類型之後,將會進行隨機分派。如果是含化療的試驗,那麼他們會被隨機分派到治療組別或化療組別。因此整體而言應該會維持平衡。我不確定是否存在任何內在偏差會導致不尋常的情況。
Sean McCutcheon - Analyst
Sean McCutcheon - Analyst
Understood. Thanks. Yeah. And just on the expectation for the -- in the 303 study for G12D performance relative to G12V and G12R, given the respective expectations for each of those mutations being treated with GMP? Thanks.
了解。謝謝。是的。另外,關於 303 研究中 G12D 的表現相對於 G12V 與 G12R 的預期——考量到以 GMP 治療這些突變各自的預期表現,您怎麼看?謝謝。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Well, you're asking a question as to -- the question is posed -- presupposed that there are very well-established differences amongst these mutations and how patients perform in a given treatment. I don't think that's so well established. In fact, if you look at multiple studies, you can find very conflicting results. It's just not particularly well established.
嗯,你問的問題是——這個問題的前提——預設這些突變之間存在非常明確、已被充分建立的差異,且會影響病患在特定治療下的表現。我不認為這點已被充分建立。事實上,如果你看多項研究,你會發現結果可能非常互相矛盾。這並沒有特別被明確建立。
So again, though, whatever it is, whatever the underlying biology is will be randomized and balanced in a given trial. So whatever that representation is should not -- shouldn't put a figure on the scale on control arm versus experimental.
不過再說一次,不論其為何——不論其背後的生物學為何,在單一試驗中都會透過隨機分派而被平衡。因此,不論那樣的代表性如何,都不應——不應在對照組與實驗組之間造成偏向。
Jack Anders - Chief Financial Officer
Jack Anders - Chief Financial Officer
Understood. Thanks.
了解。謝謝。
Operator
Operator
Faisal Khurshid, Jefferies.
Faisal Khurshid,Jefferies。
Faisal Khurshid - Analyst
Faisal Khurshid - Analyst
Hey, guys, thanks for taking the question. I just want to ask now that you've had the commissioner priority review voucher for a little bit, can you speak to what benefits you are either seeing now or expect to receive from that, above and beyond what you'd otherwise get from programs like breakthrough designation in the real-time oncology review? Thank you.
嗨,各位,謝謝讓我提問。我想請教,既然你們已經持有「局長優先審查憑證」一段時間了,能否談談你們目前看到或預期將從中獲得哪些效益——相較於你們原本可從「突破性療法認定」以及「即時腫瘤審查」等計畫中獲得的效益,這張憑證額外帶來了什麼?謝謝。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Yeah. Thanks for your question. We don't have much to offer on this particular point. We don't generally disclose a great deal about our interactions with the FDA, other than to say we do have a constructive interaction with the review team at the FDA, with the division that's handling this.
好的。謝謝你的問題。關於這一點我們沒有太多可以補充。我們一般不會大量揭露與 FDA 的互動細節;只能說,我們與 FDA 的審查團隊、以及負責此案的部門之間,確實保持建設性的互動。
It's the same group that's been handling it all along. They just now have a CNPV to manage. And we found them to be very communicative, and we have a good constructive dialogue underway. The main advantage that's been described to go with this would be a faster review process. That's really what it's all about. That's really a question for the FDA and not for us.
一直以來都是同一個團隊在處理。只是他們現在需要管理一個 CNPV。我們發現他們溝通非常順暢,我們也正在進行良好且具建設性的對話。就此所描述的主要優勢是更快的審查流程。這基本上就是重點。這其實是 FDA 的問題,而不是我們的問題。
What we'll do is we'll provide the data in the sequence that they're requesting it and as quickly as we can. And then their clock, as they see it starts ticking once they accept a submission, which means after everything is in, they've reviewed it and decide that it's an adequate submission, then they can accept it. And they've given us a suggested timeframe for how long -- how quickly they would review it. But that's not in our hands, so we don't really have any comments to make on that.
我們會做的是,依照他們要求的順序、並盡可能快速地提供資料。接著,他們的時程(就他們的定義)會在他們受理提交後開始計時;也就是說,在所有資料都提交完成、他們審閱並認定這是一份足夠的提交後,他們就可以受理。他們也給了我們一個建議的時間範圍,說明他們會在多長時間內——以多快的速度完成審查。但那不在我們掌控之中,所以我們也沒有太多評論。
Faisal Khurshid - Analyst
Faisal Khurshid - Analyst
Great. Thank you.
很好。謝謝。
Operator
Operator
Thank you. I am showing no further questions at this time. I would now like to turn it back to the Chairman and CEO, Mark Goldsmith, for closing remarks.
謝謝。目前顯示沒有其他提問。接下來我想把時間交回給董事長兼執行長 Mark Goldsmith 作結語。
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith - Chairman of the Board, President, Chief Executive Officer
Thank you, operator, and thanks to everyone else for participating today and for your continued support of Revolution Medicines.
謝謝接線員,也謝謝今天所有參與者,以及各位持續支持 Revolution Medicines。
Operator
Operator
Thank you for your participation in today's conference. This does conclude the program, and you may now disconnect.
感謝各位參與今天的電話會議。本次會議到此結束,您現在可以掛線。